We report in vivo selection of a severe acute respiratory syndrome coronavirus 2 spike mutation (Q493R) conferring simultaneous resistance to bamlanivimab and etesivimab. This mutation was isolated from a patient who had coronavirus disease and was treated with these drugs.
Keywords: COVID-19; Italy; SARS-CoV-2; bamlaniv/etesevimab; coronavirus disease; coronaviruses; receptor-binding motif; respiratory infections; severe acute respiratory syndrome coronavirus 2; spike protein; spike protein escape mutation Q493R; treatment; variant; viruses; zoonoses.